Revitalization of Damaged Skin Due to Chronic Skin Diseases

March 26, 2018 updated by: Ace Cells Lab Limited

Revitalization of Damaged Sking Due to Chronic Skin Diseases

Chronic skin disease lead to skin damage and disfiguring to the patient skin. Sometimes, achieving normal skin is not possible by the normal traditional treatment, this study is focusing on use of ACE CSD formula which is mixture of natural peptides and herbs. the main aim is to restore the normal skin appearance for the patient and control the episodes of flare.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

Psoriasis is a chronic, immune mediated (type 2 and type 17) chronic skin disease. The production of the immune proteins that leads to continuous inflammatory mediated process. The result of chronic inflammation is they hyper keratotic layer of skin which gets attacks of atopic dermatitis leading to symptoms of itching, pruritis and in situ bleeding.

ACE CSD, with the multiple factors that mediates the immune response and control the protein receptors, in addition to the multiple regeneration peptides that are specifically extracted from healthy skin of newly born sheep; in addition to multiple Chinese herbs that contains different anabolic factors was tested to be able to regenerate the damaged skin and locally modulate the immunity reactions so the skin can regenerate fully to replace the damaged skin with normal healthy skin.

Study Type

Interventional

Enrollment (Anticipated)

200

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Serbia
      • Belgrade, Serbia, 11000
        • ACE cells Lab Europe Doo
  • United Kingdom
    • Nottinghamshire
      • Nottingham, Nottinghamshire, United Kingdom, NG90 6BH
        • ACE Cells Lab Limited

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • ADULT
  • OLDER_ADULT
  • CHILD

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Chronic skin condition lasts for more than 1 year.
  • tried traditional treatment with limited or without effect.
  • not on steroids for at least 6 weeks.

Exclusion Criteria:

  • patients on steroid.
  • patients intolerable to protein or allergic to proteins
  • during pregnancy or lactation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: internvention of Chrinic skin conditions
All cases of chronic skin conditions will be included to measure the effect on the 3 of them and whihc one will respond to the treatment better
Combination product: ACE CSD
Topical application of the ACE CSD 4 times daily.
Other Names:
  • ACE Skin immune

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Regeneration of the damaged skin lesion
Time Frame: 6 - 9 months
Complete regeneration of the affected skin lesions from the skin disease.
6 - 9 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Flare control
Time Frame: 1-3 months
During the attacks of flare, the regenerated skin does not get affected nor show erythematous reaction
1-3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ace Cells Lab Limited

Investigators

  • Principal Investigator: Dr. Diana Diana, MSc Dermatology, ACE cells Lab Europe Doo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

May 1, 2018

Primary Completion (ANTICIPATED)

November 1, 2018

Study Completion (ANTICIPATED)

January 1, 2019

Study Registration Dates

First Submitted

October 7, 2017

First Submitted That Met QC Criteria

March 26, 2018

First Posted (ACTUAL)

April 2, 2018

Study Record Updates

Last Update Posted (ACTUAL)

April 2, 2018

Last Update Submitted That Met QC Criteria

March 26, 2018

Last Verified

November 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ACEcsd

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe